OXY

Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb

Retrieved on: 
Wednesday, April 3, 2024
ART, OXY, Annual report, Unitary state, Risk, Patient, Coma, Abdomen, Research, Meconium, Meconium aspiration syndrome, Human, Congenital diaphragmatic hernia, Intubation, Pharmaceutical industry

Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is delighted to announce the commencement of a program to explore the applicable use of the INSPIRA™ ART100 Device for an artificial womb for neonates in need of vital respiratory support.

Key Points: 
  • Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is delighted to announce the commencement of a program to explore the applicable use of the INSPIRA™ ART100 Device for an artificial womb for neonates in need of vital respiratory support.
  • Inspira aims to explore how this potential additional application of the INSPIRA ART100 device to provide neonates with vital respiratory support could replace the currently used mechanical ventilators.
  • "Inspira is dedicated to pushing the boundaries of medical technology to save and improve lives," remarked Dagi Ben-Noon, CEO of Inspira Technologies.
  • The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.

Inspira™ Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO's Mother with Leading Fund Manager

Retrieved on: 
Monday, April 1, 2024
OXY, Annual report, Unitary state, Risk, Form, Sale, Security (finance)

The Company has entered into a definitive agreement for the issuance and sale of an aggregate of 1,339,285 of ordinary shares at a price per share of $1.232, in a registered direct offering.

Key Points: 
  • The Company has entered into a definitive agreement for the issuance and sale of an aggregate of 1,339,285 of ordinary shares at a price per share of $1.232, in a registered direct offering.
  • The offering is expected to close on or about April 2, 2024, subject to the satisfaction of customary closing conditions.
  • The proceeds to Inspira from the offering are expected to be $1.65 million Inspira currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
  • The securities described above are being offered and sold by the Company in a registered direct offering pursuant to a "shelf" registration statement on Form F-3 (Registration No.

Inspira™ Technologies Reports Full Year 2023 Financial Results

Retrieved on: 
Monday, March 25, 2024
ART, OXY, Research, Annual report, Unitary state, IIA, Intubation, Risk, Patent, Patient, Coma, S&M, Hospital, G&A, Coagulation, Insurance, D&O, Carbon, Human, Hemolysis, Marketing, FDA, Total, Food, Pharmaceutical industry

RA'ANANA, Israel, March 25, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, today announced its financial results for the year ended December 31, 2023.

Key Points: 
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, today announced its financial results for the year ended December 31, 2023.
  • With our ground-breaking technologies and products, we are not just looking at the horizon but actively shaping it, leveraging our proprietary technologies to make a meaningful impact."
  • Total operating expenses decreased to US$12,133,000 in of the year ended December 31, 2023, from US$14,893,000 in the same period of 2022.
  • As of December 31, 2023, financial liabilities at fair value totaled US$1,470,000 compared to US$26,000.

Inspira™ Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets

Retrieved on: 
Monday, March 18, 2024
ART, OXY, Annual report, Unitary state, Risk, Patient, Coma, Research, Sale, Human, Ministry, Blood, Intubation, Medical device

"The enthusiastic support from local key-opinion leaders highlights the excitement surrounding our technology, setting the stage for its global journey.

Key Points: 
  • "The enthusiastic support from local key-opinion leaders highlights the excitement surrounding our technology, setting the stage for its global journey.
  • This method is expected to significantly reduce complications associated with traditional ventilation methods, shorten hospital stays and potentially save lives.
  • The INSPIRA™ ART (Gen 2) device is the culmination of extensive research and development efforts by the team at Inspira.
  • The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.

Inspira™ Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator

Retrieved on: 
Tuesday, March 12, 2024
ART, OXY, Annual report, Unitary state, Pressure, Risk, Patent, Inflammation, Patient, Coma, Carbon, Human, Bleeding, Hemolysis, Blood, Intubation, Medical device

The performance of the VORTX™, tested according to a regulatory guideline, was found to meet 100% of blood oxygenation requirements at various blood flow rates.

Key Points: 
  • The performance of the VORTX™, tested according to a regulatory guideline, was found to meet 100% of blood oxygenation requirements at various blood flow rates.
  • A significant leap forward in the development of safer, more effective medical devices designed to minimize patient risk and improve clinical outcomes.
  • The advanced experiments demonstrated the primary performance of the VORTX™ by collecting data on oxygenation, carbon dioxide removal, and pressures across the device during blood use.
  • This stands in stark contrast to membrane-based devices, which typically experience significant pressure drops, leading to potential damage to the patient's blood.

Inspira™ Announces Plans to Report the Primary Results for a Core Blood Oxygenation Technology Within Days

Retrieved on: 
Monday, March 4, 2024
Collection, Aggregation, Coma, Sensor, Risk, FDA, Blood, Physician, Food, Unitary state, Annual report, Nursing care plan, ART, Second generation, Food and Drug Administration, Patient, OXY, HYLA, Intubation, Human

The INSPIRA ART (Gen 2) is designed to utilize adaptive oxygenation technology, leveraging the proprietary HYLA™ blood Sensor and VORTX™ Orbiting Blood Oxygenation, to delivery oxygen straight into the blood.

Key Points: 
  • The INSPIRA ART (Gen 2) is designed to utilize adaptive oxygenation technology, leveraging the proprietary HYLA™ blood Sensor and VORTX™ Orbiting Blood Oxygenation, to delivery oxygen straight into the blood.
  • The proprietary core technology has undergone a series of testing in a variety of settings, with the results being collected and analyzed.
  • The results refer to the INSPIRA ART (Gen 2), with the new core technology potentially being suitable for replacing current solutions in medical markets dominated by leading medical device companies.
  • The Company plans to announce the primary results around the core blood oxygenation technology of the INSPIRA ART (Gen 2) within days.

Inspira™ To Host Conference Call to Discuss Investor Presentation and Announce Next Major Milestone

Retrieved on: 
Tuesday, February 27, 2024
Coma, Risk, Unitary state, Annual report, ART, Patient, Eastern Time Zone, OXY, Intubation, Human

Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, announced today that the Company President, Director and co-founder, Mr. Joe Hayon, will present an Investor Presentation and announce the Company's next major milestone.

Key Points: 
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, announced today that the Company President, Director and co-founder, Mr. Joe Hayon, will present an Investor Presentation and announce the Company's next major milestone.
  • The conference call is to be held at 9:00am Eastern Time on Monday, March 4, 2024.
  • To attend the conference call, please enter: link
    Inspira™ Technologies is an innovative medical technology company in the respiratory treatment arena.
  • For example, the Company is using forward-looking statements when it discusses the expected release of the investor presentation and announcement of its next major milestone.

Inspira™ Announces Breakthrough Update: Nears First FDA 510(k) Approval, 3 U.S. Patents Approved, $546 million in Summary Distribution Agreements

Retrieved on: 
Tuesday, February 27, 2024
Coma, Risk, FDA, Blood, Unitary state, Patent, Annual report, ART, Patient, OXY, HYLA, Intubation, Human, Medical device

Three breakthrough patents have been approved by the United States Patent and Trademark Office ("USPTO") and an additional three patent applications are pending at the USPTO for certain core technologies.

Key Points: 
  • Three breakthrough patents have been approved by the United States Patent and Trademark Office ("USPTO") and an additional three patent applications are pending at the USPTO for certain core technologies.
  • To date, the Company has signed $546 million in pre-conditioned summary distribution agreements, subject to regulatory approvals and authorizing authorities.
  • We vision the INSPIRA ART is expected to changing the medical landscape, with the VORTX orbiting blood oxygenation delivery system.
  • The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels.

Inspira™ introduces high-end platform for bio-mimicking blood parameters for development and testing of core technologies

Retrieved on: 
Thursday, February 22, 2024
Coma, Risk, Blood, Unitary state, Annual report, Carbon, ART, Element, Patient, OXY, Tissue, Intubation, Research, Human, Hemolysis, Medical device

This platform has played, and will continue to play, a vital role in advancing the development of our HYLA Blood Sensor and VORTX Orbiting blood oxygenation delivery system, which are the core technologies of the Inspira ART500.

Key Points: 
  • This platform has played, and will continue to play, a vital role in advancing the development of our HYLA Blood Sensor and VORTX Orbiting blood oxygenation delivery system, which are the core technologies of the Inspira ART500.
  • Using unique methods and equipment, our team of scientists has the ability to simulate human blood conditions based on a predefined medical profile.
  • This platform allows Inspira Technologies to control the blood parameters over a wide range, allowing it to test the efficacy and accuracy of its technologies in key scenarios, such as simulating the blood parameters of patients who may suffer from acute medical conditions.
  • The Chief Technology Officer of Inspira Technologies, Dr. Daniella Yeheskely-Hayon, stated: "Inspira Technologies focuses on developing advanced blood monitoring and oxygen delivery technologies through its high-end testing platforms which allows it perform wider range-controlled testing while minimizing the need to perform in vivo animal testing."

Inspira™ Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System

Retrieved on: 
Wednesday, February 14, 2024
Blood, United States patent law, Friction, Coma, Risk, Physician, Unitary state, Patent, Annual report, ART, Patient, OXY, HYLA, Intubation, Human, Immune system

RA'ANANA, Israel, Feb. 14, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), is a breakthrough medical technology company targeting to supersede mechanical ventilators, has received the first ever U.S. Patent approval for an orbiting blood oxygenation delivery system, a core technology of the revolutionary INSPIRA™ ART500 device. This innovation has 16 claims found to be novel.

Key Points: 
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), is a breakthrough medical technology company targeting to supersede mechanical ventilators, has received the first ever U.S. Patent approval for an orbiting blood oxygenation delivery system, a core technology of the revolutionary INSPIRA™ ART500 device.
  • The orbiting blood oxygenation delivery system (VORTX™) is designed to oxygenate blood without fiber membranes, and we believe it is expected to revolutionize the medical landscape.
  • The current fiber technologies used for blood oxygenation cause substantial damage to the patient's blood cells.
  • We believe that the orbiting blood oxygenation delivery system is another potentially game-changing core technology of the INSPIRA ART500 device, in targeting the $19 billion mechanical ventilation market.